Press releaseAd hoc announcement pursuant to Art. 53 LR Sales growth of 4.7% to CHF 1,314.2 million  Strong growth in all key business areas  Guidance for 2025 confirmed – sales growth of 3-5% and EBIT1 growth of 4-6% expected With a sales growth of 4.7% to CHF 1,314.2 million in the first four months, the Galenica Group made an excellent start t [ … ]

Galenica AG / Key word(s): AGMEGM Galenica Annual General Meeting approves all motions and elects new member of the Board of Directors 10.04.2025 / 18:12 CET/CEST Press release All motions of the Board of Directors approved with broad consensus Nadine Balkanyi-Nordmann elected as a new member of the Board of Directors Divide [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR With sales up 4.7% in the 2024 financial year, the Galenica Group grew strongly and generated consolidated net sales of CHF 3,921.1 million. As a result, Galenica outperformed market growth and gained market share in all its main business areas. Adjusted1 EBIT increased by 10.3% to CHF 211.0  [ … ]

Galenica AG / Key word(s): Personnel Galenica nominates Nadine Balkanyi-Nordmann for the Board of Directors 23.01.2025 / 07:00 CET/CEST Press release Nadine Balkanyi-Nordmann, an experienced legal, compliance and governance expert, will be recommended for election as a member of the Board of Directors at the next Annual Genera [ … ]

Press releaseAd hoc announcement pursuant to Art. 53 LR Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth (+3.5%, IQVIA, Pharmaceutical Market Switzerland, YTD December 2024). Following a solid increase  [ … ]